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Abstract 
 
Aims/hypothesis 
We investigated whether 25-hydroxyvitamin D concentration associated SNPs in the 
metabolic pathway of vitamin D show different genotype distributions between Finnish 
families with an offspring with type 1 diabetes (cases) and families with a healthy 
offspring (controls).  
 
Methods 
31 SNPs in 8 genes were studied in case and control mothers and family members 
(offspring with type 1 diabetes and healthy siblings, healthy control children and 
fathers) (n=2854). 25-hydroxyvitamin D concentration was studied in 474 case and 348 
matched control mothers during pregnancy. 
 
Results 
Genotype distributions of 13 SNPs (in the following genes: 7-dehydrocholesterol 
reductase NADSYN1/DHCR7, vitamin D receptor VDR, group-specific component GC and 
CYP27A1) that showed a nominal association with 25-hydroxyvitamin D concentration 
(p<0.05) were compared between case and control families.  SNPs in the VDR had 
different genotype distributions between case and control mothers (rs1544410 
p=0.007, rs731236 p=0.003, rs4516035 p=0.015), of which two (rs1544410 and 
rs731236) remained significant after correction for multiple testing with false discovery 
rate (FDR). Mean 25-hydroxyvitamin D concentrations during pregnancy in case and 
control mothers did not differ. 
 
Conclusions/interpretation 
Our preliminary results suggest that maternal genotypes of SNPs in the VDR may 
influence the in-utero environment and thus contribute to the early programming of 
type 1 diabetes in the fetus. It is possible that the effects are only relevant in the 
presence of vitamin D insufficiency. 
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Abbreviations 
CUBN   cubilin gene 
CYP   cytochrome p450 
DBP   vitamin D binding protein 
NADSYN1/DHCR7 7-dehydrocholesterol reductase 
GC   group-specific gene 
VDR   Vitamin D receptor 
25OHD  25-hydroxyvitamin D    
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Introduction 
 
Vitamin D deficiency, which is most commonly defined as serum 25-hydroxyvitamin D 
(25OHD) concentration lower than 50 nmol/l, may increase the risk of autoimmune 
diseases, diabetes, cancer and cardiovascular diseases [1]. The existing evidence on the 
association between vitamin D and type 1 diabetes is inconsistent. Vitamin D 
supplementation during infancy has been connected with decreased risk of type 1 
diabetes in several [2-4], but not in all studies [5]. While it has been suggested that 
vitamin D supplementation during pregnancy associates with lower risk of type 1 
diabetes, and that lower 25OHD concentrations during pregnancy associates with 
higher type 1 diabetes risk in the offspring [6,7], some studies have not been able to 
confirm this [8,9]. The prevalence of vitamin D deficiency has been shown to be higher 
in children with multiple pancreatic islet autoantibodies compared with autoantibody-
negative children, although type 1 diabetes did not progress faster in the vitamin D 
deficient group [10]. In another study, 25OHD concentration in children was not 
associated with islet autoimmunity or progression of type 1 diabetes [11]. Several genes 
important to the metabolic pathway of vitamin D have been robustly associated with 
25OHD concentrations, islet autoimmunity or type 1 diabetes [12-17].  
 
The metabolism of vitamin D consists of several hydroxylation reactions catalysed by 
the members of the cytochrome p450 (CYP) family. In the skin, vitamin D3 
(cholecalciferol) is synthesized from 7-hydrocholesterol (7-dehydrocholesterol 
reductase NADSYN1/DHCR7 catalyses the conversion of 7-dehydrocholesterol to 
cholesterol). Vitamin D3 is hydroxylated in the liver to 25OHD (CYP2R1 and CYP27A1). 
Vitamin D3 and 25OHD are transported in the circulation bound to the vitamin D 
binding protein (DBP; encoded by the group-specific component GC gene). 25OHD is 
hydroxylated to the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25OHD2) in 
the kidney or target cells (CYP27B1). Cubilin (encoded by the cubilin gene CUBN) is 
needed for the absorption of 25OHD-DBP complex into the proximal tubules of the 
kidney. 1,25OHD2 is further hydroxylated by 24-hydroxylase (CYP24A1) to the inactive 
form of vitamin D [18]. The active form of vitamin D acts through vitamin D receptor 
(VDR), which is a nuclear transcription factor that regulates transcription of vitamin D 
sensitive genes. VDRs have been detected in most tissues and it has been estimated that 
VDRs can regulate the expression of as many as 500 genes [19].  
 
The aim of the study was to compare the genotype distributions of the vitamin D 
metabolism related SNPs that show the strongest association with 25OHD 
concentration in the Finnish population between case (offspring with type 1 diabetes) 
and control families (non-diabetic offspring).    
 
Methods 
 
Study Population 
A detailed description of the study population of pregnant women (including the 
eligibility and matching criteria for case and control mothers) and the serum samples, 
as well as 25OHD analysis, has been previously published (8). Initially, 751 families with 
offspring with type 1 diabetes and 751 control families around Finland were invited to 
participate in the study. A saliva sample was collected for DNA extraction from all 
participants. DNA sample was derived from altogether 2854 individuals (512 case 
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mothers, 470 case fathers, 534 case children, 238 healthy siblings, 379 control mothers, 
340 control fathers and 381 control children). Of the 512 case mothers and of the 379 
control mothers that had a DNA sample available, 474 and 348 had a 25OHD 
concentration available, respectively. The main reasons for missing 25OHD 
concentrations were that there was no sample, or no sample left in the Finnish 
Maternity Cohort sample collection, and that the mother did not give a permission to 
use the stored serum sample for 25OHD analysis. The mean age at diagnosis of children 
with type 1 diabetes was 3.4 years (range 0-7 years). Written informed consent was 
collected from all participants. Ethical committee of the Hospital District of Helsinki and 
Uusimaa approved the study. 
 
Single Nucleotide Polymorphism Selection and Genotyping 
DNA was isolated from 2854 individuals who submitted saliva samples using Oragene® 
kits (DNA Genotek Inc., Canada). 31 single nucleotide polymorphisms (SNPs) in 8 
candidate genes were genotyped using TaqMan; VDR (rs731236, rs1544410, 
rs7975232, rs2228570, rs4516035, rs10783219); GC (rs4588, rs7041, rs12512631, 
rs2282679, rs3755967, rs17467825, rs2298850); CYP2R1 (rs10741657, rs2060793, 
rs1993116, rs7116978, rs12794714, rs10500804); CYP27B1 (rs108770112, 
rs4646536); CYP24A1 (rs6013897); CYP27A1 (rs17470271); CUBN (rs3740165); 
NADSYN1/DHCR7 (rs12785878, rs3829251, rs7944926, rs12800438, rs3794060, 
rs4945008, rs4944957). All SNPs were in genes associated with the vitamin D pathway 
and previously associated with either serum 25OHD concentrations or type 1 diabetes 
[16,17,20-27].  
 
Statistical methods 
All statistical analyses were performed using Intercooled Stata10 for Windows 
(StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: StataCorp 
LP). A linear regression was used to analyse the association between 25OHD 
concentrations and vitamin D metabolism related SNPs. Due to the known seasonal 
variation of 25OHD concentrations in Finland, the analyses were adjusted for month of 
sample collection. Pearson’s χ2 test was used for differences in proportions of case and 
control mothers by genotype. The samples size was derived from power calculations 
from our original paper (8). In SNP genotype distribution comparison multiple testing 
was controlled for using the false discovery rate (FDR) method (step-up procedure 
described by Benjamini and Hochberg [28] (0.05 as the criterion). If the original p value 
was smaller than the Benjamini-Hochberg critical value, the difference in genotype 
distribution was considered statistically significant.  
 
Results 
 
Genotyping 
All SNPs were in Hardy-Weinberg equilibrium with the exception of VDR SNP 
rs7975232, which was removed from further analyses. 95-99% of samples were 
successfully genotyped and 100% of genotypes were concordant in 120 duplicate 
samples. 
 
From the 31 SNPs we selected those that had the strongest association with 25OHD 
(with a nominal p value of <0.05) in the Finnish population (13 SNPs in 4 genes; 
NADSYN1/DHCR7, VDR, GC and CYP27A; table 1), and then compared the genotype 
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frequencies between case and control families (table 2). Three SNPs demonstrated 
different genotype distributions between mothers of children with type 1 diabetes and 
control mothers; all were located to the VDR (rs1544410 p=0.007, rs731236 p=0.003, 
and rs4516035 p=0.015). Two SNPs (rs1544410 and rs731236) remained statistically 
significant after correction for multiple testing with FDR. The difference in minor allele 
proportion between case and control mothers was not statistically significant (table 2).  
 
There were no significant differences observed between allele frequency of the 13 
studied SNPs in fathers, between case and control children, or between case children 
and their healthy siblings. Similarly, in case families no allele of the 13 studied SNPs was 
preferentially transmitted to the child with type 1 diabetes. 
 
Maternal serum 25OHD concentrations  
Mean 25OHD concentrations in case (44.9 nmol/l n=474) and control mothers (43.7 
nmol/l n=348) did not differ significantly when adjusted for month of sample collection. 
69.1% of all mothers had vitamin D deficiency (25OHD concentration <50nmol/l). Only 
3.7% of case mothers and 1.7% of control mothers had optimal vitamin D status 
(>75nmol/l) in the first trimester of pregnancy. 25OHD concentrations changed almost 
2 fold by season (March 34.3±11.0 nmol/l and in August 61.2±20.8 nmol/l; figure 1). 
 
 
Discussion 
 
In this study we investigated the genotype distributions of vitamin D metabolism 
related SNPs between families with type 1 diabetes offspring (cases) and families with 
healthy offspring (controls). Our results suggest that certain maternal VDR variants are 
associated with type 1 diabetes risk of the child independent of the child´s genotype, 
and may thus influence the in-utero environment and contribute to the early 
programming of type 1 diabetes in the fetus.  
 
In our previously published study [8] we did not find a difference in 25OHD 
concentrations between pregnant women in the first trimester who gave birth to child 
with type 1 diabetes when strictly matched with control families with no diabetic 
children, or between 25OHD concentrations during pregnancies of children with type 1 
diabetes and their healthy siblings. This is in contrast with a smaller study in Norwegian 
women [7] in which low 25OHD concentrations (mainly in the last trimester) were 
associated with an increased risk of type 1 diabetes. However, more than 70% of the 
Norwegian women had 25OHD>50 nmol/l compared with 31% in Finnish women.  
 
At this point we can only speculate the possible biological mechanisms that seem to 
connect certain maternal VDR variants with type 1 diabetes risk in the child. The 13 
SNPs that we used to compare the genotype frequencies between case and control 
mothers were selected on basis of a nominal association with 25OHD concentration. 
However, based on the data provided in the present study, there is no reason to assume 
that the connection of the VDR variants with maternal 25OHD concentration would 
necessarily explain the increase in the risk of type 1 diabetes risk in children of the 
mothers carrying these VDR variants. The association of the VDR variants with 25OHD 
concentration can rather be seen as a marker of an (unknown) effect of the variants to 
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the maternal vitamin D metabolism and/or VDR function that further associate with 
type 1 diabetes risk in the child. 
 
VDR is a transcription factor with hundreds of target genes [19]. We have previously 
reported that genetic variation of the VDR is a determinant of the expression of the VDR 
[29]. Thus it is possible that the genetic variation of the maternal VDR modifies the 
genetic effects of vitamin D of which some may, possibly together with vitamin D 
deficiency, contribute to the autoimmune process in the developing fetus and thus to 
the pathogenesis of type 1 diabetes. This would be consistent with the Diabetes 
Autoimmunity Study in the Young (DAISY) study, that demonstrated an interaction 
between VDR and protein tyrosine phosphatase, non-receptor type 2 gene (PTPN2) 
affecting the risk of progression to type 1 diabetes [13]. The fact that in the present 
study no difference in the genotype distributions of SNPs of the VDR was seen between 
children with type 1 diabetes and control children suggests that the effect is associated 
with maternal in utero environment and developmental processes during pregnancy.  
 
The VDR is expressed in placenta and its expression levels rise in late pregnancy 
compared with mid-pregnancy [30]. Since the genomic actions of ligand binding to the 
VDR include modulation of the immune system with a shift to a T helper type 2 cytokine 
response pattern [31], the genomic actions of the maternal VDR may assume a greater 
role in the presence of a reduced supply of 25OHD to the fetus determined by both 
environment and genotype. 
 
The focus in the genetics studies of type 1 diabetes has been on the affected child, and 
the effect of maternal genotype independent of the child´s genotype has not been 
described as a determinant of type 1 diabetes risk in the child before. However, the 
maternal genotype has been previously associated with for example child´s brain 
morphology [32], cognitive development [33], risk of autism [34] and atopic dermatitis 
[35]. The fact that type 1 diabetes associated autoantibodies that precede the diagnosis 
of type 1 diabetes can appear only months after birth [36], suggests a fetal 
programming of the disease.  
 
The clinical significance of our finding is not clear. Several genes contribute jointly to 
the development of type 1 diabetes and thus a certain genetic marker alone may have 
only minor impact on the disease susceptibility. Our results require independent 
validation in a larger well characterised data set of cases (mothers of children with 
early-onset type 1 diabetes) and well-matched controls and in relatively homogenous 
populations and in whom 25OHD are recorded and have genotype data available. Also it 
would be important to investigate whether genetic variation of the VDR affects 25OHD 
concentrations in the fetus for example by collecting cord blood samples. Our results 
highlight the importance of investigating factors that affect the in-utero environment 
and that may thus contribute to the early programming of type 1 diabetes. 
 
Although the present study had adequate power to detect the effect of certain maternal 
SNPs of the VDR on the type 1 diabetes risk in the child, the effect of other SNPs may not 
be seen in the present study due to limited power. If our results can be validated then 
this will be the first time that the maternal gene to environment interaction will have 
been demonstrated to influence autoimmunity in-utero which together with child’s high 
risk type 1 diabetes associated genotype determines susceptibility to type 1 diabetes. 
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The results of the present study emphasize that the in-utero environment should be a 
line of investigation when trying to find means for primary prevention of type 1 
diabetes. 
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Tables 
 
      25-hydroxyvitamin D concentrations (nmol/l)a by genotype      
SNP Gene  11  12  22  p n 
      Mean LCI UCI   Mean LCI UCI   Mean LCI UCI      
rs4945008 NADSYN1/DHCR7  42.88 41.18 44.66  41.07 39.97 42.19  39.33 37.28 41.48  0.029 766 
rs12785878 NADSYN1/DHCR7  42.94 41.25 44.69  41.03 39.95 42.14  39.21 37.19 41.34  0.021 768 
rs4944957 NADSYN1/DHCR7  42.69 40.95 44.51  41.06 39.93 42.22  38.70 37.38 41.71  0.055 728 
rs7944926 NADSYN1/DHCR7  42.97 41.24 44.78  41.04 39.94 42.17  39.20 37.16 41.35  0.022 757 
rs3794060 NADSYN1/DHCR7  42.74 41.01 44.54  40.70 39.59 41.84  38.77 36.71 40.95  0.016 733 
rs12800438 NADSYN1/DHCR7  42.98 41.29 44.74  41.12 40.03 42.23  39.34 37.31 41.47  0.024 775 
rs4516035 VDR Prom  43.03 41.22 44.92  41.23 40.17 42.32  39.50 37.69 41.40  0.022 764 
rs731236 VDR Taq1  40.29 38.86 41.78  42.12 40.91 43.36  44.02 41.54 46.66  0.025 769 
rs1544410 VDR Bsm1  40.25 38.81 41.75  42.01 40.78 43.27  43.84 41.33 46.51  0.033 747 
rs10783219 VDR  39.93 38.43 41.48  41.75 40.60 42.92  43.64 41.32 46.10  0.022 751 
rs12512631 GC  40.23 38.72 41.80  41.94 40.79 43.12  43.71 41.43 46.11  0.029 755 
rs4588  GC; T436K  42.10 40.72 43.52  40.23 38.78 41.72  38.44 35.64 41.45  0.050 737 
rs17470271 CYP27A1   42.04 40.71 43.42   40.59 39.15 42.09   39.19 36.38 42.22   0.030 750 
 
Table 1: Association of mother’s genotype with 25-hydroxyvitamin D concentrations. aadjusted for month serum sample taken; 
LCI: Lower Confidence Interval; UCI: Upper Confidence Interval; 11: Common Homozygotes; 12: Heterozygotes; 22: Rare Homozygotes. 
  
 12 
SNP Case mothers Control mothers OR (95% CI) p 
Benjamini-Hochberg 
critical valuea 
rs1544410    0.007** 0.008 
Genotypes n (%)      
AA 48 (10.2) 42 (12.0) 0.85 (0.58-1.26) 0.41  
AG 227 (48.1) 130 (37.0) 1.30 (1.10-1.53) 0.0016  
GG 197 (41.7) 179 (51.0) 0.81 (0.70-0.94) 0.0062  
Alleles n(%)      
A 323 (34.2) 214 (30.5) 1.19 (0.96-1.46) 0.11  
G 621 (65.8) 488 (69.5)    
 
rs731236    0.003** 0.004 
Genotypes n (%)      
CC 49 (9.9) 43 (12.3) 0.80 (0.55-1.18) 0.26  
CT 243 (49.0) 130 (37.2) 1.32 (1.12-1.55) 0.0007  
TT 204 (41.1) 176 (50.4) 0.82 (0.70-0.95) 0.0075  
Alleles n (%)      
C 341 (34.4) 216 (30.9) 1.17 (0.95-1.44) 0.14  
T 651 (65.6) 482 (69.1)    
 
rs4516035    0.015 0.012 
Genotypes n (%)      
CC 124 (25.1) 63 (18.4) 1.37 (1.04-1.79) 0.0215  
CT 225 (45.5) 189 (55.1) 0.83 (0.72-0.95) 0.0066  
TT 145 (29.4) 91 (26.5) 1.11 (0.89-1.38) 0.37  
Alleles n (%)      
C 473 (47.9) 315 (45.9) 1.08 (0.89-1.32) 0.43  
T 515 (52.1) 371 (54.1)    
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Table 2: Genotype distribution of 3 VDR SNPs in case and control mothers.  
amultiple testing correction with false discovery rate (FDR) approach (Benjamini-Hochberg step-up procedure). If the original p value is 
less than the Benjamini-Hochberg critical value, it is considered statistically significant  
**statistically significant after multiple testing correction with FDR approach.   
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Legends for figures 
Figure 1: Maternal 25-hydroxyvitamin D concentrations by case (black) / control 
(white) status and month of sampling. 
 
 
